was incorporated on June 29, 1983 as a private limited company and went public on April 1, 1996. Dishman Pharmaceutical & Chemicals limited manufactures and markets cost-effective, high quality chemical services and products to the global pharmaceutical and chemical industry. DISHMAN has marketing offices/wholly-owned subsidiaries at strategically important global locations.
Dishman Pharma has reported an increase of 156 per cent to Rs 38.7 crore during the first quarter of the current financial year compared to Rs 15 crore recorded in the same quarter of the previous year.
The revenues of the firm grew 30 per cent to Rs 316.3 crore compared to Rs 243 crore in the same quarter of the previous year. Dishman Pharma's operating margin is expected to be around 24 per cent. The company has made a loss on the forex to the extent of Rs 5 crore.
Technical analyst Ambrish Baliga of Karvy Stock Broking has maintained 'hold' rating on Dishman Pharmaceuticals & Chemicals Limited stock with a target of Rs 168-174.
The analyst said suggested that partial profit should be taken at aforesaid level and if you hold it for 10-12 month period, the target of Rs 240 can be attainable.
The stock of the company, on December 27, closed at Rs 144.55 on the Bombay Stock Exchange (BSE).
The share price has seen a 52-week high of Rs 275 and a low of Rs 129.15 on BSE.
The Ahmedabad based contract research and manufacturing services (CRAMS) company, Dishman Pharmaceuticals has entered into a strategic alliance with a California-based biotech company Codexis.
The Rs. 1000 crore company announced on Thursday that the 5 year alliance would let the Ahmedabad based company use Codexis' proprietary enzymatic bio-catalysis technology in order to manufacture building blocks and intermediates. Reduction of chiral compounds in the APIs and the provision of low-cost, cleaner and greener processes of manufacturing is what the company is looking forward to with this alliance.